Dystrogen Therapeutics is a life science company focused on rare diseases, it was founded based on the decades long work of Professor Maria Siemionow, MD, PhD.
The company has developed dystrophin expressing chimeric (DEC) therapy which is a candidate for the treatment of Duchenne muscular dystrophy.
This is a most common progressive muscle-wasting disorder with epidemiology of 1 case in every 3500 male birth, life expectancy of such patients is 25 years old.
